Literature DB >> 7512470

Epidemiology of high blood pressure and obesity.

F J Martínez1, J M Sancho-Rof.   

Abstract

The relationship between bodyweight and arterial pressure was first discovered early this century. More recently, epidemiological studies have confirmed the correlation between bodyweight and blood pressure in both adults and children. Serum cholesterol levels, blood glucose levels, uric acid levels and blood pressure increase with increasing bodyweight. In the presence of androgens, upper body obesity, caused by excessive intake of calories, increases cardiovascular risk factors, probably as a result of hyperinsulinaemia. The activity of Na+/K(+)-ATPase in the cells of obese subjects is reduced in a way that may be genetically determined, or may be mediated by changes in plasma insulin levels or a natural inhibitor of Na+/K(+)-ATPase. In vitro studies have shown that the potency of a non-ouabain inhibitor of Na+/K(+)-ATPase is enhanced by the presence of insulin. This may result in vascular smooth muscle having increased reactivity to pressor agents. A knowledge of cellular membrane transport may lead to a better understanding of the epidemiology of obesity-related hypertension.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7512470     DOI: 10.2165/00003495-199300462-00025

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  21 in total

1.  Sexual differentiation; Factor determining forms of obesity.

Authors:  J VAGUE
Journal:  Presse Med       Date:  1947-05-24       Impact factor: 1.228

2.  Serum-insulin in essential hypertension and in peripheral vascular disease.

Authors:  T A Welborn; A Breckenridge; A H Rubinstein; C T Dollery; T R Fraser
Journal:  Lancet       Date:  1966-06-18       Impact factor: 79.321

Review 3.  Essential hypertension: an insulin-resistant state.

Authors:  E Ferrannini; S M Haffner; M P Stern
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

Review 4.  Insulin, insulin sensitivity and hypertension.

Authors:  P Ferrari; P Weidmann
Journal:  J Hypertens       Date:  1990-06       Impact factor: 4.844

5.  Insulin action and resistance in obesity and noninsulin-dependent type II diabetes mellitus.

Authors:  J M Olefsky; O G Kolterman; J A Scarlett
Journal:  Am J Physiol       Date:  1982-07

6.  Pathogenesis of weight-related changes in blood pressure in dogs.

Authors:  A P Rocchini; C P Moorehead; S DeRemer; D Bondie
Journal:  Hypertension       Date:  1989-06       Impact factor: 10.190

Review 7.  The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension.

Authors:  N M Kaplan
Journal:  Arch Intern Med       Date:  1989-07

8.  Weight and blood pressure. Findings in hypertension screening of 1 million Americans.

Authors:  R Stamler; J Stamler; W F Riedlinger; G Algera; R H Roberts
Journal:  JAMA       Date:  1978-10-06       Impact factor: 56.272

9.  Hazards of obesity--the Framingham experience.

Authors:  M Higgins; W Kannel; R Garrison; J Pinsky; J Stokes
Journal:  Acta Med Scand Suppl       Date:  1988

Review 10.  Hyperinsulinemia or increased sympathetic drive as links for obesity and hypertension.

Authors:  M Modan; H Halkin
Journal:  Diabetes Care       Date:  1991-06       Impact factor: 19.112

View more
  4 in total

Review 1.  Regulation of the Na+/K+-ATPase by insulin: why and how?

Authors:  G Sweeney; A Klip
Journal:  Mol Cell Biochem       Date:  1998-05       Impact factor: 3.396

2.  Hypertension and obesity in African-American patients undergoing surgery.

Authors:  C O Lord
Journal:  J Natl Med Assoc       Date:  1997-08       Impact factor: 1.798

Review 3.  Hypertension and Type 2 Diabetes-The Novel Treatment Possibilities.

Authors:  Agnieszka Przezak; Weronika Bielka; Andrzej Pawlik
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

Review 4.  Molecular mechanisms underlying some major common risk factors of stroke.

Authors:  Reem Alkahtani
Journal:  Heliyon       Date:  2022-08-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.